8-K: AMS Reports Q2 2025 Net Loss Amid Strategic Expansion

American Shared Hospital Services reported a Q2 2025 net loss of $280,000 despite a 16% sequential revenue increase, driven by growth in direct patient services and declines in equipment leasing.

Summary

• Total revenue for Q2 2025 was $7,071,000, an increase of 0.2% compared to Q2 2024 and a 16% sequential increase from Q1 2025.
• The company reported a net loss attributable to American Shared Hospital Services of $280,000, or $0.04 per share, for Q2 2025, compared to net income of $3,602,000, or $0.55 per diluted share, in Q2 2024.
• Q2 2024 net income included a net bargain purchase gain of $3,679,000.
• Gross margin for Q2 2025 was $1,630,000, down from $2,468,000 in Q2 2024, primarily due to lower treatment volumes.
• Adjusted EBITDA for Q2 2025 was $1,701,000, compared to $2,010,000 in Q2 2024.
• Revenue from the direct patient services segment increased 11% year-over-year to $3,500,000 in Q2 2025, driven by new centers in Rhode Island and Puebla, Mexico.
• Revenue from the medical equipment leasing segment decreased 8% year-over-year to $3,571,000 in Q2 2025.
• Gamma Knife revenue increased 25% sequentially but decreased 5% compared to Q2 2024.
• LINAC revenue increased 7% sequentially and 34% compared to Q2 2024.
• Proton Beam Radiation Therapy revenue increased 17% sequentially but decreased 21% compared to Q2 2024.
• For the six months ended June 30, 2025, total revenue increased 7% to $13,183,000 compared to $12,272,000 for the first half of 2024.
• Net loss attributable to American Shared Hospital Services for the first half of 2025 was $905,000, or $0.14 per share, compared to net income of $3,721,000, or $0.57 per diluted share, for the first half of 2024.
• Cash, cash equivalents, and restricted cash totaled $11,331,000 at June 30, 2025, slightly up from $11,275,000 at December 31, 2024.
• Shareholders' equity (excluding non-controlling interests) was $24,481,000, or $3.78 per outstanding share, at June 30, 2025, down from $25,183,000, or $3.92 per outstanding share, at December 31, 2024.

Sentiment

Score: 4

Explanation: The filing presents mixed results. While there is positive sequential revenue growth and clear strategic expansion initiatives, the significant year-over-year decline in net income (shifting from profit to loss) and decreased gross margin/EBITDA are concerning. The prior year's one-time gain explains part of the net income difference, but underlying profitability metrics still show a downturn. The long-term growth strategy is positive, but current financial performance indicates challenges.

Positives

• Total revenue increased 16% sequentially compared to Q1 2025.
• LINAC revenue increased 34% compared to Q2 2024 and 7% sequentially.
• Direct patient services revenue increased 11% year-over-year to $3,500,000, driven by new centers in Rhode Island and Puebla, Mexico.
• Patient volumes increased compared to the previous quarter.
• The company highlights four years of consecutive revenue growth and three years of sustained profitability (referring to broader trends, not just Q2 2025).
• Successful acquisition of a majority interest in three Rhode Island radiation therapy treatment centers.
• Opening of the new Puebla, Mexico center.
• Received Certificate of Need approvals for the first radiation therapy treatment center in Bristol, Rhode Island, and a proton beam radiation therapy treatment center in Johnston, Rhode Island.
• Maintains a strong balance sheet with $11,331,000 in cash, cash equivalents, and restricted cash at June 30, 2025.

Negatives

• Reported a net loss of $280,000 for Q2 2025, a significant decline from net income of $3,602,000 in Q2 2024 (which included a $3,679,000 bargain purchase gain).
• Gross margin decreased to $1,630,000 in Q2 2025 from $2,468,000 in Q2 2024, primarily due to lower treatment volumes.
• Adjusted EBITDA decreased to $1,701,000 for Q2 2025 from $2,010,000 in Q2 2024.
• Medical equipment leasing segment revenue decreased 8% year-over-year to $3,571,000 in Q2 2025.
• Gamma Knife revenue decreased 5% compared to Q2 2024, attributed to the expiration of three customer contracts and lower PBRT volumes.
• Total proton beam radiation therapy revenue decreased 21% to $1,921,000 in Q2 2025 from $2,420,000 in Q2 2024 due to lower volumes and cyclical fluctuations.
• Shareholders' equity decreased to $24,481,000 at June 30, 2025, from $25,183,000 at December 31, 2024.

Risks

• Risks associated with economic and market conditions.
• Risks of variability of financial results between quarters.
• Risks inherent in the Gamma Knife, proton therapy, and direct patient care services businesses.
• Risks of changes to CMS reimbursement rates or reimbursement methodology.
• Risks related to the timing, financing, and operations of the Company's Gamma Knife, proton therapy, and direct patient care services businesses.
• Risk of expanding within or into new markets.
• Risk that the integration or continued operation of acquired businesses could adversely affect financial results.
• Risk that current and future acquisitions may negatively affect the Company's financial position.

Future Outlook

The company expects further long-term growth from the new Esprit installation in Guadalajara, Mexico, anticipated to start up in late 2025. Additionally, Certificate of Need approvals for new radiation therapy treatment centers in Bristol, Rhode Island, and a proton beam radiation therapy treatment center in Johnston, Rhode Island, are expected to expand the Rhode Island footprint and growth potential. Management anticipates further recovery in treatment volumes into the back half of 2025 and continues to pursue additional strategic tuck-in acquisitions to bolster its footprint and growth potential.

Management Comments

• Gary Delanois, Chief Executive Officer: "I am pleased to see patient volumes increased compared to last quarter and we remain laser focused on expanding our business model and operational enhancements to further position us for robust long-term growth."
• Gary Delanois, Chief Executive Officer: "As we look into the second half of this year, we expect further long-term growth from the new Esprit being installed in Guadalajara, Mexico that is expected to startup in late 2025."
• Scott Frech, Chief Financial Officer: "Our second quarter of 2025 was highlighted by an increase in treatment volumes compared to last quarter and we continue to expect to see further recovery into the back half of this year."
• Scott Frech, Chief Financial Officer: "Our linear accelerator business growth is a shining example of the strength of our diversification strategy where we reported 34% revenue growth quarter over quarter and 7% sequentially."
• Ray Stachowiak, Executive Chairman: "We are proud to highlight the past four years of consecutive revenue growth and the past three years of sustained profitability, as we remain focused on building long-term shareholder value."
• Ray Stachowiak, Executive Chairman: "Our successful acquisition of a majority interest in three Rhode Island radiation therapy treatment centers and the opening of our new Puebla, Mexico center highlight the recent strength of our growth strategy."
• Ray Stachowiak, Executive Chairman: "We also continue to pursue additional strategic tuck in acquisitions to further bolster out footprint and growth potential."

Industry Context

The company's strategic shift towards direct patient care services and away from a sole leasing model aligns with a broader healthcare industry trend focusing on integrated service delivery and specialized treatment centers. Investments in advanced technologies like LINAC and proton beam therapy reflect the growing demand for sophisticated cancer treatment modalities. Geographic expansion into Mexico and new centers in Rhode Island indicate a strategy to tap into new or underserved markets, enhancing patient access to specialized oncology care.

Stakeholder Impact

• Shareholders: Experience mixed financial results with sequential revenue growth but a significant year-over-year net loss and decreased profitability metrics. Long-term value creation is tied to the success of strategic growth initiatives.
• Patients: Benefit from the expansion of direct patient care services and new treatment centers in Rhode Island and Puebla, Mexico, increasing access to advanced cancer treatment.
• Employees: The focus on operational efficiencies and cost controls may imply pressure, but growth initiatives could create new opportunities.
• Customers (leasing segment): The expiration of three Gamma Knife customer contracts indicates some churn in the medical equipment leasing business.

Next Steps

• Startup of the new Esprit installation in Guadalajara, Mexico, expected in late 2025.
• Further expansion of the Rhode Island footprint and growth potential following Certificate of Need approvals for new treatment centers in Bristol and Johnston, Rhode Island.
• Continued pursuit of additional strategic tuck-in acquisitions.
• Focus on targeted strategic initiatives to improve efficiency and maximize profitability.
• Continued focus on operational efficiencies and cost controls.
• Expectation of further recovery in treatment volumes into the back half of 2025.

Key Dates

Recommendation

While the company demonstrates strategic growth through new direct patient service centers and sequential revenue increases, the significant year-over-year decline in net income and gross margin, even when accounting for the prior year's one-time gain, raises profitability concerns. The shift from a profitable quarter to a net loss, coupled with decreased Adjusted EBITDA, suggests operational headwinds or increased costs associated with expansion. The long-term growth strategy and new project pipeline are positive, but current financial performance indicates a need for sustained improvement in profitability before a 'buy' recommendation. Investors should hold to observe if the strategic initiatives translate into improved bottom-line results in the coming quarters.

Keywords

Stereotactic radiosurgery, Radiation therapy, Cancer treatment, Gamma Knife, LINAC, Proton Beam, Medical equipment leasing, Direct patient care, Healthcare services, Oncology, Hospital services, SEC filing, Financial results